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executive summary
Much progress has been achieved since the publication of “A
Compendium of Strategies to Prevent Healthcare-Associated
Infections in Acute Care Hospitals”1-7 in October 2008. In
2009, the US Department of Health and Human Services
(HHS) released a national healthcare-associated infection
(HAI) action plan8 focused on preventing central line–
associated bloodstream infections (CLABSI), catheter-asso-
ciated urinary tract infections (CAUTI), surgical site infec-
tions (SSI), methicillin-resistant Staphylococcus aureus
(MRSA) bloodstream infections, and Clostridium difficile in-
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table 1. Grading of the Quality of Evidence
Grade Definition
I. High Highly confident that the true effect lies close to that of the estimated size and direction of the
effect. Evidence is rated as high quality when there is a wide range of studies with no major
limitations, there is little variation between studies, and the summary estimate has a narrow
confidence interval.
II. Moderate The true effect is likely to be close to the estimated size and direction of the effect, but there is
a possibility that it is substantially different. Evidence is rated as moderate quality when there
are only a few studies and some have limitations but not major flaws, there is some variation
between studies, or the confidence interval of the summary estimate is wide.
III. Low The true effect may be substantially different from the estimated size and direction of the effect.
Evidence is rated as low quality when supporting studies have major flaws, there is important
variation between studies, the confidence interval of the summary estimate is very wide, or
there are no rigorous studies, only expert consensus.
note. Based on Grades of Recommendation, Assessment, Development, and Evaluation (GRADE)13 and the
Canadian Task Force on Preventive Health Care.14
fections (CDI) in acute care hospitals. In 2011, the Centers
for Medicare and Medicaid Services (CMS) began requiring
acute care hospitals to report specific types of HAI data to
CMS through the Centers for Disease Control and Preven-
tion’s (CDC’s) National Healthcare Safety Network (NHSN)
in order to receive their full annual reimbursement updates,
vastly expanding the breadth of hospitals contributing sur-
veillance information into the NHSN national repository of
HAI data.9 Also in 2011, HHS launched a public-private ini-
tiative called the Partnership for Patients: Better Care, Lower
Costs, aimed at improving the quality, safety, and affordability
of US healthcare.10 Based on HAI surveillance data collected
by NHSN, substantial improvements have been achieved in
preventing CLABSI and SSI within the last several years.11
Continued progress in healthcare epidemiology and imple-
mentation science research has led to improvements in our
understanding of effective HAI prevention strategies. Despite
these advancements, HAIs continue to affect about 1 out of
every 25 hospitalized patients, leading to substantial morbidity,
mortality, and excess healthcare expenditures,12 and there are
persistent gaps between recommendations and practice.
The following is a summary of the strategies to prevent
HAIs in acute care hospitals presented in the 2014 Compen-
dium updates. Criteria for classifying recommendations as
basic practices versus special approaches and for grading the
quality of supporting evidence are described below. Each in-
fection prevention recommendation was assigned a quality-
of-evidence rating (high p I, moderate p II, or low p III)
adapted from criteria utilized by the Grades of Recommen-
dation, Assessment, Development, and Evaluation (GRADE)
system13 and the Canadian Task Force on Preventive Health
Care14 (Table 1).
Strategies to Prevent CAUTI
I. Basic practices for preventing CAUTI: recommended for
all acute care hospitals
A. Provide appropriate infrastructure for preventing CAUTI
1. Provide and implement written guidelines for cath-
eter use, insertion, and maintenance (quality of evi-
dence: III).
2. Ensure that only trained, dedicated personnel insert
urinary catheters (quality of evidence: III).
3. Ensure that supplies necessary for aseptic technique
for catheter insertion are available and conveniently
located (quality of evidence: III).
4. Implement a system for documenting the following
in the patient record: physician order for catheter
placement, indications for catheter insertion, date
and time of catheter insertion, name of individual
who inserted catheter, nursing documentation of
placement, daily presence of a catheter and mainte-
nance care tasks, and date and time of catheter re-
moval. Record criteria for removal and justification
for continued use (quality of evidence: III).
5. Ensure that there are sufficient trained personnel and
technology resources to support surveillance for cath-
eter use and outcomes (quality of evidence: III).
B. Perform surveillance for CAUTI if indicated on the basis
of facility risk assessment or regulatory requirements
1. Identify the patient groups or units in which to con-
duct surveillance on the basis of risk assessment, con-
sidering frequency of catheter use and potential risk
(eg, types of surgery, obstetrics, critical care; quality
of evidence: III).
2. Use standardized criteria, such as NHSN definitions,
to identify patients who have a CAUTI (numerator
data; quality of evidence: III).
3. Collect information on catheter-days and patient-
days (denominator data) and indications for catheter
insertion for all patients in the patient groups or units
being monitored (quality of evidence: III).
4. Calculate CAUTI rates and/or standardized infection
ratio (SIR) for target populations (quality of evidence:
III).
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5. Use surveillance methods for case finding that are
documented to be valid and appropriate for the in-
stitution (quality of evidence: III).
6. Consider providing unit-specific feedback (quality of
evidence: III).
C. Provide education and training
1. Educate healthcare personnel (HCP) involved in the
insertion, care, and maintenance of urinary catheters
about CAUTI prevention, including alternatives to
indwelling catheters, and procedures for catheter in-
sertion, management, and removal (quality of evi-
dence: III).
2. Assess healthcare professional competency in catheter
use, catheter care, and maintenance (quality of evi-
dence: III).
D. Use appropriate technique for catheter insertion
1. Insert urinary catheters only when necessary for pa-
tient care and leave in place only as long as indications
remain (quality of evidence: II).
2. Consider other methods for bladder management,
such as intermittent catheterization, where appro-
priate (quality of evidence: II).
3. Practice hand hygiene (based on CDC or World
Health Organization [WHO] guidelines) immediately
before insertion of the catheter and before and after
any manipulation of the catheter site or apparatus
(quality of evidence: III).
4. Insert catheters following aseptic technique and using
sterile equipment (quality of evidence: III).
5. Use sterile gloves, drape, and sponges; a sterile or
antiseptic solution for cleaning the urethral meatus;
and a sterile single-use packet of lubricant jelly for
insertion (quality of evidence: III).
6. Use as small a catheter as possible consistent with
proper drainage, to minimize urethral trauma (qual-
ity of evidence: III).
E. Ensure appropriate management of indwelling catheters
1. Properly secure indwelling catheters after insertion to
prevent movement and urethral traction (quality of
evidence: III).
2. Maintain a sterile, continuously closed drainage sys-
tem (quality of evidence: III).
3. Replace the catheter and the collecting system using
aseptic technique when breaks in aseptic technique,
disconnection, or leakage occur (quality of evidence:
III).
4. For examination of fresh urine, collect a small sample
by aspirating urine from the needleless sampling port
with a sterile syringe/cannula adaptor after cleansing
the port with disinfectant (quality of evidence: III).
5. Obtain larger volumes of urine for special analyses
aseptically from the drainage bag (quality of evidence:
III).
6. Maintain unobstructed urine flow (quality of evi-
dence: III).
7. Employ routine hygiene; cleaning the meatal area
with antiseptic solutions is unnecessary (quality of
evidence: III).
II. Special approaches for preventing CAUTI
1. Implement an organization-wide program to identify
and remove catheters that are no longer necessary using
one or more methods documented to be effective (qual-
ity of evidence: II).
2. Develop a protocol for management of postoperative
urinary retention, including nurse-directed use of in-
termittent catheterization and use of bladder scanners
(quality of evidence: II).
3. Establish a system for analyzing and reporting data on
catheter use and adverse events from catheter use (qual-
ity of evidence: III).
Strategies to Prevent CDI
I. Basic practices for prevention and monitoring of CDI: rec-
ommended for all acute care hospitals
1. Encourage appropriate use of antimicrobials (quality of
evidence: II).
2. Use contact precautions for infected patients, single-
patient room preferred (quality of evidence: III for hand
hygiene, II for gloves, III for gowns, III for single-patient
room).
3. Ensure cleaning and disinfection of equipment and the
environment (quality of evidence: III for equipment, III
for environment).
4. Implement a laboratory-based alert system to provide
immediate notification to infection prevention and con-
trol and clinical personnel about newly diagnosed CDI
patients (quality of evidence: III).
5. Conduct CDI surveillance and analyze and report CDI
data (quality of evidence: III).
6. Educate HCP, environmental service personnel, and hos-
pital administration about CDI (quality of evidence: III).
7. Educate patients and their families about CDI as ap-
propriate (quality of evidence: III).
8. Measure compliance with CDC or WHO hand hygiene
and contact precaution recommendations (quality of
evidence: III).
II. Special approaches for preventing CDI
A. Approaches to minimize C. difficile transmission by HCP
1. Intensify the assessment of compliance with process
measures (quality of evidence: III).
2. During outbreaks or in settings with hyperendemic
CDI, perform hand hygiene with soap and water as
the preferred method before exiting the room of a
patient with CDI (quality of evidence: III).
3. Place patients with diarrhea under contact precau-
tions while C. difficile testing is pending (quality of
evidence: III).
4. Prolong the duration of contact precautions after the
patient becomes asymptomatic until hospital dis-
charge (quality of evidence: III).
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B. Approaches to minimize C. difficile transmission from
the environment
1. Assess the adequacy of room cleaning (quality of evi-
dence: III).
2. Use an Environmental Protection Agency–approved
sporicidal disinfectant or diluted sodium hypochlo-
rite for environmental cleaning and disinfection. Im-
plement a system to coordinate with environmental
services if it is determined that sodium hypochlorite
is needed for environmental disinfection (quality of
evidence: III).
C. Approaches to reduce the risk of CDI if C. difficile is
acquired
1. Initiate an antimicrobial stewardship program (qual-
ity of evidence: II).
Strategies to Prevent SSI
I. Basic practices for preventing SSI: recommended for all
acute care hospitals
1. Administer antimicrobial prophylaxis according to evi-
dence-based standards and guidelines (quality of evi-
dence: I).
2. Do not remove hair at the operative site unless the
presence of hair will interfere with the operation. Do
not use razors (quality of evidence: II).
3. Control blood glucose during the immediate postop-
erative period for cardiac surgery patients (quality of
evidence: I) and noncardiac surgery patients (quality of
evidence: II).
4. Maintain normothermia (temperature of 35.5C or
more) during the perioperative period (quality of evi-
dence: I).
5. Optimize tissue oxygenation by administering supple-
mental oxygen during and immediately following sur-
gical procedures involving mechanical ventilation (qual-
ity of evidence: I).
6. Use alcohol-containing preoperative skin preparatory
agents if no contraindication exists (quality of evi-
dence: I).
7. Use impervious plastic wound protectors for gastroin-
testinal and biliary tract surgery (quality of evidence: I).
8. Use a checklist based on the WHO checklist to ensure
compliance with best practices to improve surgical pa-
tient safety (quality of evidence: I).
9. Perform surveillance for SSI (quality of evidence: II).
10. Increase the efficiency of surveillance through utili-
zation of automated data (quality of evidence: II).
11. Provide ongoing feedback of SSI rates to surgical and
perioperative personnel and leadership (quality of evi-
dence: II).
12. Measure and provide feedback to providers regarding
rates of compliance with process measures (quality of
evidence: III).
13. Educate surgeons and perioperative personnel about
SSI prevention (quality of evidence: III).
14. Educate patients and their families about SSI preven-
tion as appropriate (quality of evidence: III).
15. Implement policies and practices aimed at reducing
the risk of SSI that align with evidence-based standards
(eg, CDC, Association for periOperative Registered
Nurses, and professional organization guidelines; qual-
ity of evidence: II).
II. Special approaches for preventing SSI
1. Screen for S. aureus and decolonize surgical patients
with an antistaphylococcal agent in the preoperative set-
ting for high-risk procedures, including some ortho-
pedic and cardiothoracic procedures (quality of evi-
dence: II).
2. Perform antiseptic wound lavage (quality of evidence: II).
3. Perform an SSI risk assessment (quality of evidence: III).
4. Observe and review operating room personnel and the
environment of care in the operating room (quality of
evidence: III).
5. Observe and review practices in the postanesthesia care
unit, surgical intensive care unit (ICU), and/or surgical
ward (quality of evidence: II).
Strategies to Prevent CLABSI
I. Basic practices for preventing and monitoring CLABSI:
recommended for all acute care hospitals
A. Before insertion
1. Provide easy access to an evidence-based list of in-
dications for central venous catheter (CVC) use to
minimize unnecessary CVC placement (quality of
evidence: III).
2. Require education of HCP involved in insertion, care,
and maintenance of CVCs about CLABSI prevention
(quality of evidence: II).
3. Bathe ICU patients over 2 months of age with a chlor-
hexidine preparation on a daily basis (quality of evi-
dence: I).
B. At insertion
1. Have a process in place to ensure adherence to in-
fection prevention practices at the time of CVC in-
sertion in ICU and non-ICU settings, such as a check-
list (quality of evidence: II).
2. Perform hand hygiene prior to catheter insertion or
manipulation (quality of evidence: II).
3. Avoid using the femoral vein for central venous access
in obese adult patients when the catheter is placed
under planned and controlled conditions (quality of
evidence: I).
4. Use an all-inclusive catheter cart or kit (quality of
evidence: II).
5. Use ultrasound guidance for internal jugular catheter
insertion (quality of evidence: II).
6. Use maximum sterile barrier precautions during CVC
insertion (quality of evidence: II).
7. Use an alcoholic chlorhexidine antiseptic for skin
preparation (quality of evidence: I).
This content downloaded from 128.252.139.7 on Sat, 8 Nov 2014 13:58:13 PM
All use subject to JSTOR Terms and Conditions
executive summary: 2014 compendium updates 971
C. After insertion
1. Ensure appropriate nurse-to-patient ratio and limit the
use of float nurses in ICUs (quality of evidence: I).
2. Disinfect catheter hubs, needleless connectors, and
injection ports before accessing the catheter (quality
of evidence: II).
3. Remove nonessential catheters (quality of evidence: II).
4. For nontunneled CVCs in adults and children, change
transparent dressings and perform site care with a
chlorhexidine-based antiseptic every 5–7 days or im-
mediately if the dressing is soiled, loose, or damp;
change gauze dressings every 2 days or earlier if the
dressing is soiled, loose, or damp (quality of evidence:
II).
5. Replace administration sets not used for blood, blood
products, or lipids at intervals not longer than 96
hours (quality of evidence: II).
6. Use antimicrobial ointments for hemodialysis cath-
eter-insertion sites (quality of evidence: I).
7. Perform surveillance for CLABSI in ICU and non-
ICU settings (quality of evidence: I).
II. Special approaches for preventing CLABSI
1. Use antiseptic- or antimicrobial-impregnated CVCs in
adult patients (quality of evidence: I).
2. Use chlorhexidine-containing dressings for CVCs in pa-
tients over 2 months of age (quality of evidence: I).
3. Use an antiseptic-containing hub/connector cap/port
protector to cover connectors (quality of evidence: I).
4. Use silver zeolite–impregnated umbilical catheters in
preterm infants (in countries where it is approved for
use in children; quality of evidence: II).
5. Use antimicrobial locks for CVCs (quality of evidence:
I).
6. Use recombinant tissue plasminogen activating factor
once weekly after hemodialysis in patients undergoing
hemodialysis through a CVC (quality of evidence: II).
Strategies to Prevent MRSA
I. Basic practices for preventing MRSA transmission and in-
fection: recommended for all acute care hospitals
1. Conduct an MRSA risk assessment (quality of evidence:
III).
2. Implement an MRSA monitoring program (quality of
evidence: III).
3. Promote compliance with CDC or WHO hand hygiene
recommendations (quality of evidence: II).
4. Use contact precautions for MRSA-colonized and
MRSA-infected patients (quality of evidence: II).
5. Ensure cleaning and disinfection of equipment and the
environment (quality of evidence: II).
6. Educate HCP about MRSA (quality of evidence: III).
7. Implement a laboratory-based alert system that notifies
HCP of new MRSA-colonized or MRSA-infected pa-
tients in a timely manner (quality of evidence: III).
8. Implement an alert system that identifies readmitted or
transferred MRSA-colonized or MRSA-infected patients
(quality of evidence: III).
9. Provide MRSA data and outcome measures to key stake-
holders, including senior leadership, physicians, nursing
staff, and others (quality of evidence: III).
10. Educate patients and their families about MRSA (qual-
ity of evidence: III).
II. Special approaches
A. Active surveillance testing (AST)
1. Implement an MRSA AST program as part of a multi-
faceted strategy to control and prevent MRSA (quality
of evidence: II).
2. Screen HCP for MRSA infection or colonization if
they are epidemiologically linked to a cluster of
MRSA infections (quality of evidence: III).
B. MRSA decolonization therapy
1. Provide targeted decolonization therapy to MRSA-
colonized patients in conjunction with an AST pro-
gram (quality of evidence: II).
2. Provide universal decolonization to ICU patients
(quality of evidence: I).
C. Use of gowns and gloves for all contact with patients
and the patient care environment
1. Use gowns and gloves when providing care to or
entering the room of adult ICU patients (quality of
evidence: II).
Strategies to Prevent Ventilator-Associated
Pneumonia (VAP)
Adult Patients
I. Basic practices to prevent VAP and other ventilator-asso-
ciated events in adult patients: interventions with little risk
of harm that decrease duration of mechanical ventilation,
length of stay, mortality, and/or costs
A. Avoid intubation if possible
1. Use noninvasive positive pressure ventilation (NIPPV)
whenever feasible (quality of evidence: I).
B. Minimize sedation
1. Manage ventilated patients without sedatives when-
ever possible (quality of evidence: II).
2. Interrupt sedation once a day (spontaneous awak-
ening trials) for patients without contraindications
(quality of evidence: I).
3. Assess readiness to extubate once a day (spontaneous
breathing trials) in patients without contraindications
(quality of evidence: I).
4. Pair spontaneous breathing trials with spontaneous
awakening trials (quality of evidence: I).
C. Maintain and improve physical conditioning
1. Provide early exercise and mobilization (quality of
evidence: II).
D. Minimize pooling of secretions above the endotracheal
tube cuff
1. Provide endotracheal tubes with subglottic secretion
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drainage ports for patients likely to require greater than
48 or 72 hours of intubation (quality of evidence: II).
E. Elevate the head of the bed
1. Elevate the head of the bed to 30–45 (quality of
evidence: III).
F. Maintain ventilator circuits
1. Change the ventilator circuit only if visibly soiled or
malfunctioning (quality of evidence: I).
2. Follow CDC/Healthcare Infection Control Practices
Advisory Committee guidelines for sterilization and
disinfection of respiratory care equipment (quality of
evidence: II).
II. Special approaches
A. Interventions that decrease duration of mechanical ven-
tilation, length of stay, and/or mortality but for which
insufficient data on possible risks are available
1. Use selective decontamination of the oropharynx to
decrease the microbial burden of the aerodigestive
tract (quality of evidence: I).
B. Interventions that may lower VAP rates but for which
there are insufficient data at present to determine their
impact on duration of mechanical ventilation, length
of stay, and mortality
1. Perform oral care with chlorhexidine (quality of evi-
dence: II).
2. Administer prophylactic probiotics (quality of evi-
dence: II).
3. Use ultrathin polyurethane endotracheal tube cuffs
(quality of evidence: III).
4. Provide automated control of endotracheal tube cuff
pressure (quality of evidence: III).
5. Instill saline before tracheal suctioning (quality of
evidence: III).
6. Provide mechanical tooth brushing (quality of evi-
dence: III).
Neonatal Patients
I. Basic practices for preterm neonates: interventions with
minimal risk of harm that may lower VAP rates
A. Avoid intubation if possible
1. Consider nasal continuous positive airway pressure
ventilation with or without nasal intermittent me-
chanical ventilation as an alternative to intubation
(quality of evidence: I).
B. Minimize the duration of mechanical ventilation
1. Manage patients without sedation whenever possible
(quality of evidence: III).
2. Assess readiness to extubate daily (quality of evidence:
III).
3. Avoid unplanned extubations and reintubations
(quality of evidence: III).
4. Provide regular oral care with sterile water (extrap-
olated from studies in adults, no data in preterm
neonates; quality of evidence: III).
5. Minimize breaks in the ventilator circuit (extrapo-
lated from studies in adults, no data in preterm neo-
nates; quality of evidence: III).
6. Change the ventilator circuit only if visibly soiled or
malfunctioning (extrapolated from studies in adults
and children, no data in preterm neonates; quality of
evidence: III).
II. Special approaches for preterm neonates
A. Interventions with minimal risks of harm but unknown
impact on VAP rates
1. Lateral recumbent positioning (quality of evidence:
III).
2. Reverse Trendelenburg positioning (quality of evi-
dence: III).
3. Closed/in-line suctioning (quality of evidence: III).
Pediatric Patients
I. Basic practices for pediatric patients: interventions with min-
imal risk of harm and some data that they lower VAP rates
A. Avoid intubation if possible
1. Use NIPPV in selected populations whenever feasible
(quality of evidence: II).
B. Minimize the duration of mechanical ventilation
1. Assess readiness to extubate daily in patients without
contraindications (quality of evidence: II).
2. Avoid unplanned extubations and reintubations
(quality of evidence: III).
C. Provide regular oral care
1. Provide regular oral care (quality of evidence: III).
D. Elevate the head of the bed
1. Elevate the head of the bed unless medically contra-
indicated (quality of evidence: III).
E. Maintain ventilator circuits
1. Change ventilator circuits only when visibly soiled or
malfunctioning (quality of evidence: II).
2. Remove condensate from the ventilator circuit fre-
quently (quality of evidence: III).
3. Suction oral secretions before each position change
(quality of evidence: III).
F. Endotracheal tube selection and maintenance
1. Use cuffed endotracheal tubes (quality of evidence:
III).
2. Maintain cuff pressure and volume at the minimal
occlusive settings to prevent clinically significant air
leaks around the endotracheal tube, typically 20 cm
of water (quality of evidence: III).
II. Special approaches for pediatric patients
A. Interventions with evidence of benefit in adult pa-
tients and minimal risks of harm but limited data in pe-
diatric populations
1. Interrupt sedation once a day (quality of evidence:
II).
2. Administer prophylactic probiotics (quality of evi-
dence: III).
3. Use endotracheal tubes with subglottic secretion
drainage ports (quality of evidence: III).
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Strategies to Prevent HAIs through Hand Hygiene
I. Basic practices for hand hygiene: recommended for all
acute care hospitals
1. Select appropriate products (quality of evidence: II).
2. Provide convenient access to hand hygiene equipment
and products by placing them strategically and assuring
that they are refilled routinely as often as required (qual-
ity of evidence: III).
3. Involve HCP in choosing products (quality of evidence:
III).
4. Perform hand hygiene with an alcohol-based hand rub
or, alternatively, an antimicrobial or nonantimicrobial
soap for the following indications (quality of evidence:
II).
5. Perform hand hygiene with antimicrobial or nonanti-
microbial soap when hands are visibly soiled (quality
of evidence: II).
6. Assess unit- or institution-specific barriers to hand hy-
giene with frontline HCP for the purpose of identifying
interventions that will be locally relevant (quality of
evidence: III).
7. Implement a multimodal strategy (or “bundle”) for im-
proving hand hygiene adherence to directly address the
organization’s most significant barriers (quality of evi-
dence: II).
8. Educate, motivate, and ensure competency of HCP (any-
one caring for the patient on the institution’s behalf)
about proper hand hygiene (quality of evidence: III).
9. Measure hand hygiene adherence via direct observation
(human observers), product volume measurement, or
automated monitoring (quality of evidence: II).
10. Provide feedback to HCP on hand hygiene perfor-
mance (quality of evidence: III).
II. Special approaches for hand hygiene practices
1. During norovirus outbreaks, in addition to contact pre-
cautions requiring the use of gloves, consider prefer-
ential use of soap and water after caring for patients
with known or suspected norovirus infection (quality
of evidence: III).
2. During C. difficile outbreaks or in settings with hyper-
endemic CDI, in addition to contact precautions re-
quiring the use of gloves, consider preferential use of
soap and water after caring for patients with known or
suspected CDI (quality of evidence: III).
introduction
The major aim of the original documents published in 2008
and the 2014 Compendium updates15-21 is to provide acute
care hospitals with up-to-date, practical, relatively concise
expert guidance to assist in prioritizing and implementing
HAI prevention efforts. These articles are the products of a
highly collaborative effort led by the Society for Healthcare
Epidemiology of America (SHEA), the Infectious Diseases
Society of America (IDSA), the American Hospital Associa-
tion (AHA), the Association for Professionals in Infection
Control and Epidemiology (APIC), and The Joint Commis-
sion, with major contributions from representatives of a num-
ber of organizations and societies with content expertise, in-
cluding the CDC, the Institute for Healthcare Improvement
(IHI), the Pediatric Infectious Diseases Society (PIDS), the
Society for Critical Care Medicine (SCCM), the Society for
Hospital Medicine (SHM), and the Surgical Infection Society
(SIS).
Consistent with the 2008 version of the Compendium,
the recommendations within the updated documents are
largely based on previously published HAI prevention
guidelines available from a number of organizations, in-
cluding the Healthcare Infection Control Practices Advisory
Committee (HICPAC), the CDC, SHEA, IDSA, and APIC,
as well as other relevant published literature and the con-
sensus of the content experts who served as section panel
members. The Compendium does not reflect a complete
systematic review of the medical literature and is not meant
to supplant previously published guidelines and systematic
reviews but instead aims to provide acute care hospitals with
a summary of practical, relatively concise guidance based
largely on these documents. An expert review panel eval-
uated each article in detail to assess the included material
and to ensure that the level of evidence assigned to each
recommendation was appropriate.
major changes to the compendium
In addition to updated recommendations in each of the
articles, major changes in the 2014 updates to the Com-
pendium include a new guidance document that reviews
evidence-based strategies to improve and assess hand hy-
giene performance. In addition, a new segment has been
added to each of the Compendium articles that briefly de-
scribes examples of published implementation strategies and
provides references that hospitals can access for more de-
tailed information.
Seven Compendium articles are now included, with six
focused on specific types of HAIs and one new section focused
on hand hygiene improvement strategies. Each section con-
tains a statement of concern, a brief summary of previously
described detection and prevention approaches, recom-
mended infection prevention strategies, proposed perfor-
mance measures, and examples of implementation strategies
for consideration.
Each infection prevention recommendation was assigned
a quality-of-evidence rating (high p I, moderate p II, or
low p III) adapted from criteria utilized by the GRADE
system13 and the Canadian Task Force on Preventive Health
Care14 (Table 1).
Recommendations are categorized as either (1) basic prac-
tices that should be adopted by all acute care hospitals or (2)
special approaches that can be considered for use in locations
This content downloaded from 128.252.139.7 on Sat, 8 Nov 2014 13:58:13 PM
All use subject to JSTOR Terms and Conditions
974 infection control and hospital epidemiology august 2014, vol. 35, no. 8
and/or populations within hospitals when HAIs are not con-
trolled after full implementation of basic practices. The de-
cisions to categorize a recommendation as a basic practice
versus a special approach were made through consensus of
the section writing panel with input from expert panel mem-
bers based on the quality of evidence and the balance between
desirable and potentially undesirable effects of various inter-
ventions. Basic practices include recommendations where the
potential to impact HAI risk clearly outweighs the potential
for undesirable effects.
Special approaches include recommendations where the
intervention is likely to reduce HAI risk but where there is
concern about the risks for undesirable outcomes, where the
quality of evidence is low, or where evidence supports the
impact of the intervention in select settings (eg, during out-
breaks) or for select patient populations. Hospitals can pri-
oritize their efforts by initially focusing on implementation
of the prevention approaches listed as basic practices. If HAI
surveillance or other risk assessment suggests that there are
ongoing opportunities for improvement, hospitals should
then consider adopting some or all of the prevention strategies
listed as special approaches. These can be implemented in
specific locations or patient populations or can be imple-
mented hospital-wide, depending on outcome data, risk as-
sessment, and/or local requirements.
methods
SHEA and the IDSA Standards and Practice Guidelines Com-
mittee recruited two experts in the prevention of HAIs to be
section panel leads for each Compendium article. Additional
section panel members representing SHEA, IDSA, CDC, The
Joint Commission, APIC, PIDS, and SCCM were selected as
appropriate to their areas of expertise. Expert panel members
with broad healthcare epidemiology and infection prevention
expertise were convened to review draft manuscripts and to
provide input to each section panel. An advisory group con-
sisting of representatives from the five major partnering or-
ganizations (SHEA, IDSA, APIC, The Joint Commission, and
AHA) provided broad oversight over the Compendium writ-
ing process (see Compendium Leadership section at end of
the text). All participants complied with the SHEA and IDSA
policies on conflict of interest disclosure.
Literature Review and Analysis
Section panel members reviewed previously published guide-
lines, systematic reviews, and meta-analyses as well as relevant
literature published since 2008.
Consensus Development
Section panel members for each Compendium article met as
needed via teleconference to discuss recommendations, rank-
ing of the quality of evidence for these recommendations,
and classification as basic practices, special approaches, or
unresolved issues. Section leads assigned responsibilities to
panel members. Compendium article drafts were reviewed
and final versions were approved by the respective section
panel members.
Review and Approval Process
A critical stage in the development process is peer review.
Peer reviewers are relied on for expert, critical, and unbiased
scientific appraisals of the documents. SHEA and IDSA em-
ployed a process that included multilevel review and approval.
Comments were obtained from the expert panel members
who complied with the SHEA and IDSA policies on conflict
of interest disclosure. In addition, the 5 partnering organi-
zations as well as a number of stakeholder organizations pro-
vided comments, support, and endorsement (see Endorsing
and Supporting Organizations section at end of text). Finally,
the guidance documents were reviewed and approved by the
SHEA Guidelines Committee, the IDSA Standards and Prac-
tice Guidelines Committee, and the board of directors of
SHEA, IDSA, APIC, and The Joint Commission before dis-
semination.
Disclosure of Conflicts of Interest
All members of the Compendium section panels, expert
panel, and advisory group complied with the IDSA and SHEA
policies on conflicts of interest, which require disclosure of
any financial or other interest within the past 2 years that
might be construed as constituting an actual, potential, or
apparent conflict. All participants were provided with the
SHEA conflicts of interest disclosure statement and were
asked to identify ties to companies developing products that
might be affected by promulgation of the Compendium. In-
formation was requested regarding employment, consultan-
cies, stock ownership, honoraria, research funding, expert
testimony, and membership on company advisory commit-
tees, and participants with potential conflicts were required
to submit a plan detailing the process that would be used to
avoid conflicts. Decisions were made by the Compendium
co-chairs and a disclosure review committee on a case-by-
case basis as to whether an individual’s role should be limited
as a result of a conflict. Potential conflicts are listed in the
Acknowledgments of each section.
Mechanism for Updating the Compendium
At annual intervals, the SHEA Guidelines Committee, in col-
laboration with IDSA, AHA, APIC, and The Joint Commis-
sion, will determine the need for revisions to the Compen-
dium on the basis of an examination of the current literature.
If necessary, the section leads and other content experts will
be consulted to discuss the need for changes.
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